Rheumatology: Current Research
Open Access

Department of Rheumatology, Office and Karl Landsteiner Institute for Clinical Rheumatology, Hollabrunn, Austria

Biography

Dr. Peter Spellitz is an eminent professional at the Department Department of Out-Patient, Rheumazentrum Wien Oberlaa Center, Vienna, Austria. Peter Spellitz's area of expertise includes Rheumazentrum .

Publications

• Research Article   
  Januskinase Inhibitors to Treat Rheumatoid Arthritis: Real World Data Match Clinical Trial Results. An Evaluation by BioReg, the Austrian Registry for Biologicals, Biosimilars, and Targeted Synthetic DMARDS in the Treatment of Inflammatory Rheumatic
  Author(s): Burkhard F. Leeb*, Peter Spellitz, Gabriele Eichbauer-Sturm, Manfred Herold, Miriam Stetter, Rudolf Puchner, Franz St. Singer and Ruth Fritsch-Stork
  
  Background: Whether the safety and efficacy of Januskinase Inhibitors (JAKis) in daily routine treatment of Rheumatoid Arthritis (RA) match the respective clinical trial results is of crucial clinical interest, however, growing, but still limited corresponding evidence is available. Patients and methods: Data, including adverse events, disease activity scores, patient-related outcomes, and response as well as persistence rates, of all RA patients receiving JAKi treatment registered in the BioReg database were retrieved. The results were described according to those of pivotal clinical trials of JAKis. Analyses were performed using descriptive statistics, such as mean value comparisons, and by drawing patient trajectories. Results: One-hundred-and twenty-two patients (mean age 64 years; 83.9% female, 60.5% Rheumatoi.. View More»
  DOI: 10.35248/2161-1149.21.11.288

  Abstract HTML PDF